- {{heading}}
- Ab01202-1.1 Anti-gp120 [u5.5]
- HIV
- Mouse IgG1
- Purified
- Ships in 5-6 weeks
- Ab01202-23.0 Anti-gp120 [u5.5]
- HIV
- Rabbit IgG
- Purified
- Ships in 5-6 weeks
Recombinant monoclonal antibody to gp120. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma u5.5.
UniProt Accession Number of Target Protein: U5JCI1
Alternative Name(s) of Target: Ru5.5; gp120; Envelope glycoprotein gp160; Env polyprotein; transmembrane protein gp41; TM gp41; glycoprotein 41; gp41; surface protein gp120; SU gp120; mu5.5
Immunogen: Mice were immunised with HTLV-IIIMN cells. Spleen cells were harvested and hybridomas generated.
Specificity: Specific to the principal neutralizing determinant (PND) of the V3 region of gp120 of HIV-1. It is reactive against peptides longer than 11 mer containing the sequence IHIGPGRAFYT (Okamoto et al, 1998).
Application Notes: Has been tested against the primary field isolates of Japanese hemophiliacs seropositive for HIV-1 and protect SCID-hu mice from infection from these isolates. u5.5 was used as a humanized antibody and found to have a high neutralization activity. As of such it has been proposed as a protective antibody, however its epitope specificity gives it a limited range (Okamoto et al, 1998). It has been used in Western Blots to detect the V3 epitope of HIV-1 (Honda et al, 1995).
Antibody first published in:
D’Souza, P Monoclonal antibodies to gp160: characterization of epitopes
that elicit neutralizing activity. In The Third International Workshop Antibody
Serological Project The Third International Workshop Antibody
Serological Project. Keystone, National Institutes of Health, Bethesda, MD.,
p. 25. PMID:
Note on publication:
There is no online record of this study, but it is referenced in the sequencing paper as the source of the antibody (Okamoto et al, 1998).